期刊文献+
共找到6篇文章
< 1 >
每页显示 20 50 100
化合物物理化学性质的优化及其对类药性质的影响 被引量:2
1
作者 张婷 彭红 金鑫 《江西中医药》 2016年第11期75-78,共4页
为了加快新药研发的速率,本文通过对实验药物和成功药物的物理化学性质进行统计对比和分析,找出了一些能够优化化合物物理化学性质的规则和规律,对新药的结构设计和修饰进行指导,从而影响和改善化合物的类药性质,使医药企业节约成本和时... 为了加快新药研发的速率,本文通过对实验药物和成功药物的物理化学性质进行统计对比和分析,找出了一些能够优化化合物物理化学性质的规则和规律,对新药的结构设计和修饰进行指导,从而影响和改善化合物的类药性质,使医药企业节约成本和时间,研发出疗效更好的新药。 展开更多
关键词 发现 物理化学性质 优化 类药性质
全文增补中
如何提高新药研发的成功率:化合物的物理化学性质的优化及其对类药性质的影响 被引量:1
2
作者 熊照明 《常州大学学报(自然科学版)》 CAS 2014年第3期64-68,共5页
近年来,为提高新药研发的成功率,通过对实验药物的物理化学性质进行统计分析,并和成功药物进行比较对照,试图找出化合物的物理化学性质与它们的类药性质的关系,从而可以指导新药的设计,加快新药研发的成功率和研发速度。
关键词 理化性质 研发 类药性质
下载PDF
上市药物与中止药物理化性质差异探讨
3
作者 倪炜 郑新羽 +2 位作者 王熳炯 毛斐 李剑 《中国药物化学杂志》 CAS CSCD 北大核心 2018年第6期494-503,共10页
目的探讨上市及中止药物关键理化性质的相同与差异规律,用于指导药物研发工作者在新药开发早期阶段设计更易于成药的化合物,减少新药研发失败率,推动新药研发进程。方法基于上市及中止药物数据库药物的化学结构,对比分析上市及中止药物... 目的探讨上市及中止药物关键理化性质的相同与差异规律,用于指导药物研发工作者在新药开发早期阶段设计更易于成药的化合物,减少新药研发失败率,推动新药研发进程。方法基于上市及中止药物数据库药物的化学结构,对比分析上市及中止药物分子量(Mr)、脂水分布系数(log P)、解离常数(p Ka)、重原子比例(R)等关键理化性质的相同与差异。结果与结论与中止药物相比,上市药物的Mr整体分布在较低的Mr区间,表明Mr小的候选药物发展成为上市药物的几率更高;在log P大于3的各单个区间内,中止全集和口服药物所占比例全部高于上市药物,表明当候选药物log P大于3时,其研发失败几率增大;上市中枢神经系统(CNS)药物的log P分布与中止CNS药物的相差不大,表明CNS药物研发中,log P不再是目前药物研发失败的主要因素;上市药物和中止药物的p Ka和重原子比例分布相差不大,表明p Ka和重原子比例不是目前药物研发失败的主要因素。 展开更多
关键词 类药性质 理化性质 中止
原文传递
基于PTP1B活性区域靶向中药成分治疗糖尿病的虚拟筛选及动力学模拟验证
4
作者 杨子博 支爽 +2 位作者 代霖霖 王慧 李冬冬 《现代药物与临床》 CAS 2024年第4期848-856,共9页
目的利用计算机辅助技术,在中药成分中针对蛋白酪氨酸磷酸酶1B(PTP1B)多个作用位点筛选抑制剂。方法整理TCMSP数据库,利用Autodock Vina和Ledock筛选,利用数据库预测中药成分类药性质、生物活性、药动学,通过动力学模拟验证结合稳定性... 目的利用计算机辅助技术,在中药成分中针对蛋白酪氨酸磷酸酶1B(PTP1B)多个作用位点筛选抑制剂。方法整理TCMSP数据库,利用Autodock Vina和Ledock筛选,利用数据库预测中药成分类药性质、生物活性、药动学,通过动力学模拟验证结合稳定性。结果2,3,7-trihydroxy-5-(3,4-dihydroxy-E-styryl)-6,7,8,9-tetrahydro-5H-benzocycloheptene有良好的类药性质,满足类药原则,有良好的药动学性质,与PTP1B多个活性位点共同作用并稳定结合。结论2,3,7-trihydroxy-5-(3,4-dihydroxy-E-styryl)-6,7,8,9-tetrahydro-5H-benzocycloheptene具有治疗糖尿病的潜在可能性,可以对其做进一步结构优化、实验验证。 展开更多
关键词 糖尿病 蛋白酪氨酸磷酸酶1B 抑制剂 虚拟筛选 类药性质 生物活性 动学 2 3 7-trihydroxy-5-(3 4-dihydroxy-E-styryl)-6 7 8 9-tetrahydro-5H-benzocycloheptene
原文传递
A high-performance liquid chromatography with fluorescence detection method for the simultaneous quantitation of monoamine neurotransmitters and their metabolites in subregions of rat brain 被引量:2
5
作者 徐鹏 白燕平 +3 位作者 杨海松 李静 卢炜 凌笑梅 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2015年第7期458-466,共9页
Abstract: In the presem study, we simultaneously quantified the levels of monoamine neurotransmitters (MANTs) and their metabolites (levodopa, norepinephrine, epinephrine, dopamine, 5-HT, 3,4-dihydroxyphenylacetic... Abstract: In the presem study, we simultaneously quantified the levels of monoamine neurotransmitters (MANTs) and their metabolites (levodopa, norepinephrine, epinephrine, dopamine, 5-HT, 3,4-dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindole-3-acetic acid) in different brain subregions of rats using a newly developed simple, sensitive and selective high-performance liquid chromatography with fluorescence detection (HPLC-FLD) method. In this new HPLC-FLD method, analytes were directly extracted and separated without deriveatization step within 20 min. The FLD wavelength was set at 280 nm and 330 nm for excitation and emission, respectively. The analytes were separated on an Agilent Eclipse Plus Cls column (4.6 mm×150 mm, 5.0 μm) equipped with an Agilent XDB-C18 security guard column (4.6 mm×12.5 mm, 5.0 lam), and the column temperature was maintained at 35 ℃. The mobile phase for elution was isocratic. The mobile phase consisted of citric acid buffer (50 mmol/L citric acid, 50 mmol/L sodium acetate, 0.5 mmol/L octane sulfonic acid sodium salt, 0.5 mmol/L Na2EDTA and 5 mmol/L triethylamine, pH 3.8) and methanol (90:10, v/v) at a flow rate of 1.0 mL/min. The detection limit (DL) was 0.9-23 nM for all the MANTs and their metabolites with a sample volume of 50 μL. The method was shown to be highly reproducible in terms of peak area (intraday, 0.08%-1.85% RSD, n = 5). The simultaneous measurement of these MANTs and their metabolites improved our understanding of the neurochemistry in the central nervous system (CNS) in relation to different addictive drugs (methamphetamine, heroin and their mixture) in drug-addicted rat models. 展开更多
关键词 High performance liquid chromatography Fluorescence detection Monoamine neurotransmitters Addictive drug Brain subregions Corticolimbic system
原文传递
SAR of tricyclic sulfones as γ-secretase inhibitors
6
作者 COLE David ASBEROM Ted +12 位作者 BARA Tom BENNETT Chad BURNETT Duane A. CLADER John DOMALSKI Martin GREENLEE William J. HYDE Lynn JOSIEN Hubert McBRIAR Mark McKITTRICK Brian PISSARNITSKI Dmitri RAJAGOPALAN Murali SASIKUMAR Thavalakulamgara 《Science China Chemistry》 SCIE EI CAS 2011年第11期1688-1701,共14页
Novel tricyclic sulfones as γ-secretase inhibitors have been reported by this laboratory for the treatment of Alzheimer's disease. Compounds in this series have comparable or better in vitro activities and in viv... Novel tricyclic sulfones as γ-secretase inhibitors have been reported by this laboratory for the treatment of Alzheimer's disease. Compounds in this series have comparable or better in vitro activities and in vivo efficacies than sulfonamide analogues re- ported previously by this laboratory. Based on the previously reported tricyclic sulfone scaffold, additional SAR studies of C ring were carried out. Various C-ring structures including cyclohexane, pyran, and piperidine were tolerated. Additionally, the 7- and 8- positions of the C-ring were identified as the best sites to introduce substituent for modulating the pharmacokinetic properties of compounds from this series. 展开更多
关键词 tricyclic sulfones T-secretase Alzheimer's disease INHIBITORS
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部